Here is the design of a clinical trial:

Official Title: Impact of a Hospital Medication Expertise on the Rate of Unplanned Hospitalizations at 3 Months of Patients Residing in Nursing Homes (EPAD)

Included conditions:
- Age Problem

Study Armgroups:
- {'label': 'experimental group', 'type': 'EXPERIMENTAL', 'description': 'Patient living in nursing homes a tele-expertise will be performed', 'interventionNames': ['Other: tele-expertise']}
- {'label': 'control group', 'type': 'NO_INTERVENTION', 'description': 'Patient living in nursing homes will performed a normal care.'}

Interventions:
- {'type': 'OTHER', 'name': 'tele-expertise', 'description': 'Tele-expertise consists of the remote realization of a multi-professional medication review (clinical pharmacist and doctor / geriatrician), ie a complete and systematic analysis of sociodemographic, clinical, biological and pharmaceutical data transmitted in such a way standardized at the EHMP and aimed at optimizing the therapeutics of the resident patient of the EHPAD requesting tele-expertise.\n\nTele-expertise is realized in three stages, that are\n\n* the transmission, the collection and the organization of the data,\n* the analysis of the data and their confrontation with the referential and recommendations\n* the writing of a Personalized Pharmaceutical Plan', 'armGroupLabels': ['experimental group']}

Primary Outcomes:
- {'measure': 'number of unplanned hospitalizations', 'description': 'The main endpoint is the rate of unplanned hospitalizations (all structures) of nursing home residents', 'timeFrame': '6 months'}

Please estimate the sample size based on the assumption: 
90% power, two-tailed significance level of 0.05, 25% loss to follow-up.
Sample size
        On the basis of a unplanned hospital admission rate of 25% over a 3-month period [23] and taking into consideration the results of a study evaluating the impact at 8âweeks of medication review on admission to nursing home [24], we estimate a unplanned hospital admission rate of 10% in the experimental group. The initial sample size of 292 patients provided 90% power to detect this difference at a two tailed significance level of 0.05. Assuming possibly 25% of patients lost to follow-up, a total of 364 patients is required (182 per group) (Fig.Â 1).
Fig. 1Flow diagram of the study protocol